Slide 1: Financial results of the Diagnostyka Group for Q3 2025
Financial results of the Diagnostyka Group for Q3 2025 21 November 2024
Slide 2: Presenters
Presenters: Jakub Swadźba Paweł Chytła Bartosz Cieślicki President of the Management Board, Vice President of the Management Board, Deputy Chief Financial Officer Chief Executive Officer (CEO) Chief Financial Officer (CFO)
Slide 3: Q3 2025 operational highlights
Q3 2025 operational highlights
Slide 4: Q3 2025 summary
Q3 2025 summary Financial highlights Operational highlights Diagnostic tests volume The Group’s revenue Opening of Development of the 43.0 PLN 615.1 a state-of-the-art My Health million million laboratory in Rzeszów Programme (+10.9% y/y) (+26.6% y/y) Net profit attributable to Execution of 16 contr
Slide 5: Financial results
Diagnosty! Financial results
Slide 6: Strong year-on-year revenue growth maintained
Strong year-on-year revenue growth maintained Revenue from contracts with customers (PLN million) +18.1% MLT Contribution to revenue: +24.0% Total + High revenue growth y/y: +26.6% +26.6% 1,792.2 in Q3 2025 (including: +19.6% in MLT); Q3 2024 24.0% in 9M 2025 (including: +18.1% in MLT) 85.9 588.3 61
Slide 7: Revenue growth driven by increased test volumes and higher prices
Revenue growth driven by increased test volumes and higher prices Diagnostic tests volume (million) Contribution to diagnostic tests volume +10.9% +9.0% Q3 2024 + Increase in tests volume: 43.7 131.9 B2C 43.0 121,1 +10.9% in Q3 2025 (including +10.5% in MLT) 38.8 0.419 0.130 0.149 16,4% and +9.0% in
Slide 8: Operating expenses growing faster than revenue
Operating expenses growing faster than revenue Operating expenses (PLN million) Increase in operating + In Q3 2025, operating expenses grew year on year at a expenses (%): 27.5% 24.4% faster rate than revenue from contracts with customers, Increase in revenue from 26.6% 24.0% mainly due to regulator
Slide 9: Recurring EBITDA at PLN 466.3 million, up 21.6% y/y
Recurring EBITDA at PLN 466.3 million, up 21.6% y/y Recurring EBITDA (PLN million) Recurring EBITDA margin (%): 25.7% 26.0% 24.9% 26.5% 26.0% + Recurring EBITDA margin: a 0.9 pp decline y/y in Q3 2025, to 24.9%, and a 0.5 pp decline in 9M 2025, to 26.0% +21.6% +22.3% + The weaker recurring EBITDA ma
Slide 10: Faster year-on-year growth in net profit vs recurring EBITDA
Faster year-on-year growth in net profit vs recurring EBITDA Change Change Change Change Q3 2024 Q3 2025 9M 2024 9M 2025 y/y (%) y/y y/y (%) y/y Key drivers of the change in net profit in 9M 2025: Recurring EBITDA 124.4 152.2 27.8 22.3% 383.6 466.3 82.7 21.6% Recurring EBITDA margin 25.7% 24.9% -0.9
Slide 11: Robust cash flow supporting the Group's further growth
Robust cash flow supporting the Group's further growth Free cash flow1 (PLN million) Capex (PLN million) FCF/EBITDA 96.2% 107.3% 83.9% 85.4% 90.8% Capex excl. 6.1% 6.4% 8.9% 6.6% 6.9% M&A/revenue2 +30.7% 178.2 421,9 53,9 126.0 +8.4% 322,9 73.0 71.8 30,5 164,1 17,6 127,6 35,4 117,7 39.1 124,3 9.5 95,
Slide 12: Net debt and working capital under control
Net debt and working capital under control + Net working capital rose to PLN 189.3 million in Q3 2025, mainly due to a PLN 50.3 million growth in trade receivables, resulting from higher sales and consolidation of diagnostic imaging companies (PLN 31.6 million) + Net debt grew to PLN 971.4 million r
Slide 13: 2025 Outlook for the Diagnostyka Group
2025 Outlook for the Diagnostyka Group Revenue from contracts with customers low/mid 20s % y/y growth Average price per test low/mid teens % y/y growth Diagnostic tests volume high single digit % y/y growth Recurring EBITDA margin close to 2024 Capex excl. M&A PLN 130-170 million M&A capex PLN 80-10
Slide 14: Appendices
Diagnosty! Appendices
Slide 15: Interim condensed consolidated statements of comprehensive income and financial position
Interim condensed consolidated statement of Interim condensed consolidated statement of financial position (PLN thousand) comprehensive income (PLN thousand) Change As at As at Change As at As at Change 9M 2025 9M 2024 Change (%) Q3 2025 Q3 2024 ASSETS EQUITY AND LIABILITIES (%) 30 Sep 2025 31 Dec 2
Slide 16: Interim condensed consolidated statement of cash flows
Interim condensed consolidated statement of cash flows (PLN thousand) 9M 2025 9M 2024 9M 2025 9M 2024 Profit (loss) before tax 267,983 226,876 Cash flows from financing activities Adjustments to profit before tax: 198,819 149,871 Non-controlling interest in capital increase at subsidiaries 4,985 -0
Slide 17: Contact
Contact Michał Błasiński Investor Relations Director michal.blasinski@diag.pl Disclaimer This presentation (the “Presentation”) has been prepared by Diagnostyka S.A. (“Diagnostyka”) to share selected information about the Diagnostyka Group (“Diagnostyka Group”) with shareholders, analysts, business